Rep. Daniel S. Goldman sold Viatris (VTRS)
Rep. Daniel S. Goldman (D-NY-10) · $1K–$15K · traded Mar 6, 2023
- Transaction
- Sold (partial)
- Amount
- $1K–$15K
- Owner
- Not stated
- Traded
- Mar 6, 2023
- Disclosed
- Apr 17, 2023
- Days to disclose
- 42
- Asset type
- Stock
- As filed
- Viatris Inc.
- Industry
- Drug Manufacturers - Specialty & Generic · Healthcare
Other trades in this filing
All of Goldman's trades →- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$50K–$100K
Sold VONOVIA SE ADR CMN (VONOY)
$50K–$100K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought VOLKSWAGEN AKTIENGESELLSCHAFT ADR CMN (VWAPY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Sold (partial) Vodafone Group Public Limited Company VOD
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought VAT GROUP AG ADR CMN (VACNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) UPM-KYMMENE OYJ ADR CMN (UPMMY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Swedbank AB (publ) SWDBY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Bought Sumitomo Mitsui Financial Group SMFG
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold SOMPO JAPAN NIPPONKOA HLDGS IN ADR CMN (SMPNY)
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
Sold (partial) Shiseido Company, Limited SSDOY
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$1K–$15K
$1K–$15K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
- Apr 17, 2023$15K–$50K
Bought SALMAR ASA ADR CMN (SALRY)
$15K–$50K · Traded Mar 31, 2023 · disclosed Apr 17, 2023
Recent Congress trades in VTRS
- Dec 15, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Nov 18, 2025 · disclosed Dec 15, 2025
- May 8, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded Apr 8, 2025 · disclosed May 8, 2025
- Apr 7, 2025$1K–$15K
Rep. Gilbert Ray Cisneros, Jr. (D-CA-31)
$1K–$15K · Traded Mar 31, 2025 · disclosed Apr 7, 2025
- Mar 27, 2025$1K–$15K
Rep. Robert P. Bresnahan, Jr. (R-PA-8)
$1K–$15K · Traded Feb 25, 2025 · disclosed Mar 27, 2025
- Dec 5, 2024$1K–$15K
- May 19, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Apr 10, 2023 · disclosed May 19, 2023
- Feb 24, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 24, 2023
- Sep 15, 2022$1K–$15K
Sen. Tommy Tuberville (R-AL)
$1K–$15K · Traded Aug 1, 2022 · disclosed Sep 15, 2022
Company context for VTRS
Recent records for the company. These may have been published before or after this trade; compare the dates before drawing a connection.
VTRS: third_quarter 2026 lobbying report
S. 891, the Bipartisan Health Care Act Part D Formulary Design and Generic Drug Tiering HR 4132 / S.2027 - Prescription Information Modernization Act Medicaid Generics Penalty Implementation of the Inflation Reduction Act Drug Shortages S. 2658, The Medication Affordability and Patent Integrity Act IP Issues related to generic medicines Patent Settlements Trade issues related to generic medicines Pharmaceutical supply chain S.3778: Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act S.3841: Last Sale Valuation Act Policy related to corporate
Public: Oct 20, 2026, 8:43 PM EDTOriginal source ↗VTRS: third_quarter 2026 lobbying report
Policy and oversight related to the generic pharmaceutical industry. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations and National Defense Authorization Act (S. 1071). Trade issues related to generic medicines.
Public: Oct 19, 2026, 4:20 PM EDTOriginal source ↗VTRS: third_quarter 2026 lobbying report
S. 1302 - Increasing Transparency in Generic Drug Applications Act; Supply Chain Issues; E-labeling; Inflation Reduction Act Implementation; Improving Generic Drug Access; Drug Shortages; Medicaid Generics Penalty.
Public: Oct 7, 2026, 6:43 AM EDTOriginal source ↗
From a periodic transaction report filed under the STOCK Act. Amounts are the ranges members report. Nothing here is investment advice.